Scisparc announces successful final phase iia results, meeting end points of its phase iia alzheimer disease patients with agitation trial

Topline results using the company's sci-110 met the trial's primary and secondary end points, demonstrating high safety profile and reduced agitation topline results using the company's sci-110 met the trial's primary and secondary end points, demonstrating high safety profile and reduced agitation
SPRC Ratings Summary
SPRC Quant Ranking